Solvay Creon May Soon Find Competitors At The Trough
Following a successful advisory committee, Solvay's Creon appears likely to become the only pancreatic enzyme product on the market with an approved NDA - at least for a little while
More from Archive
More from Pink Sheet
• By
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
• By
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
• By
HHS Secretary Kennedy's new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.